Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF).
about
Critical Questions about PARADIGM-HF and the FutureHeart Failure: Diagnosis, Management and UtilizationThe neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartanNeprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chancesAngiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyondGenetic Factors Influencing B-type Natriuretic Peptide-Mediated Production of Cyclic Guanosine Monophosphate and Blood Pressure Effects in Heart Failure Patients.Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure TrialCombined Angiotensin Receptor Antagonism and Neprilysin Inhibition.Geographic variations in the PARADIGM-HF heart failure trial.Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction.Neprilysin inhibition in chronic kidney diseaseDecade in review--heart failure: 10 Years of progress in HF research--what have we learned?New drugs and devices in the pipeline for heart failure with reduced ejection fraction versus heart failure with preserved ejection fraction.Heart failure therapies in 2014: Mixed results for heart failure therapies.Novel RAAS agonists and antagonists: clinical applications and controversies.LCZ696 (angiotensin-neprilysin inhibition): the new kid on the heart failure block?New medical therapies for heart failure.A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction.Sacubitril/valsartan (LCZ696) for the treatment of heart failure.Long-term outcomes in patients with critical limb ischemia and heart failure with preserved or reduced ejection fraction.Angiotensin receptor neprilysin inhibitor LCZ696: pharmacology, pharmacokinetics and clinical development.Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study.New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment.Gender differences in the effects of cardiovascular drugs.Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.The need to apply the best therapy in heart failure - the era after PARADIGM-HF.Sacubitril/ValsartanThe Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics.Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction.Heart Failure and Kidney Disease.What constitutes optimal neurohumoral antagonism in chronic heart failure?Nongenetic markers in heart failure.Insights into implementation of sacubitril/valsartan into clinical practice.Eligibility of sacubitril-valsartan in a real-world heart failure population: a community-based single-centre study.Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study.Publishing in a heart failure journal-where lies the scientific interest?Erratum to: Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor.Outpatient management of chronic heart failure.Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor.
P2860
Q26741029-22310F03-D60D-4EDD-8367-653A1F5C2234Q26745543-2E57D907-D431-46D5-BA0D-6B923C2EC916Q26747165-68746F9D-6EC2-4896-86E2-A360881DAAF5Q27027707-A24F7912-F703-4CE0-A3F7-A0C5A566118CQ28088583-DA42501F-E6B8-429B-BD1A-8E4BDA9DE345Q36390713-25F7048B-E6D6-4DA7-BA5F-077A6E335DDEQ36477865-F93550D5-202B-449C-BD48-ECF10E1AFEA2Q36709153-13EAAA8B-7943-499D-98B7-D032E11EE9CCQ37410283-2C2E34E9-0A06-414A-BDC1-8C0A804581DAQ37595978-224D91A4-C3B8-4E9E-82CB-D3E1FD8E5833Q38241522-FA677DD4-57BD-43F3-9E5A-BB37FF1E2C11Q38245288-52744315-D044-42EF-9574-3CA41BC325CEQ38248398-F08A7AB6-414E-4512-9C18-FA6855270C34Q38307955-D31A33EB-EC73-477D-B468-E1C511CF4FBEQ38349798-C129E8FE-DA8B-4A50-9526-BDC0A9D77961Q38416785-7F866B7B-1D65-4026-B8FC-1C7551CCB1F5Q38594785-EA7AC9E6-C572-4672-A87B-075E368427FEQ38655266-E2A2B282-4CEE-4244-947F-73A727A580A2Q38661061-C9A0A587-BFBC-487A-9A65-2BBA7B2B9233Q38685935-EFB8D9AB-C1EC-4DFC-90D8-7BAD33E7CE13Q38790076-110C54C1-9560-4519-9A60-4EEFA3E11FC0Q38885540-D95F28D0-E904-49C0-AA18-4D1882252835Q38944536-A34CB769-2480-4B17-BE9A-E896E72350CEQ38955252-88B4D2EB-F53C-4862-972A-C53D04D0B3A1Q39193538-2ABD1CAC-B994-49F6-9054-137C23447F1CQ39247505-5CFAE154-C15F-4AFE-A974-91A869D42844Q41549509-8870A868-06A9-4A19-845C-2FE4AEAD58BBQ42564219-BAE974F1-3219-42E8-AF05-A7A1C35A3772Q45952980-A5241265-1C61-4003-B85A-6CE7AF277474Q47264002-29847AD8-FB39-42EA-83EB-DCA56A721B77Q47437642-22440DEE-3634-4EC8-AA53-E0B60A2CD28DQ47814853-5197BE3C-89CA-4B02-BC57-0E211CB50721Q48065394-74463A8A-7E6A-4F18-BF8D-33100831A6D6Q49718855-C3D49481-1E53-4C50-86D5-12A783BC597EQ49972504-6C401D69-B24B-4165-83F1-0BD9ED56E855Q50026199-8242DFA4-0251-439E-B782-75E4E7C4C5A7Q50048824-B03D1FEC-434B-4173-87EB-9EA9F9FD8DA3Q50634411-22E51F8B-8AE5-4897-B26A-868932B70E01Q50998627-166FB406-A144-4BB7-86B6-8C66BEAC0CD2Q51016419-F4B0E86C-F356-4687-A686-8FFBC1EA7FA9
P2860
Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF).
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Baseline characteristics and t ...... t failure trial (PARADIGM-HF).
@ast
Baseline characteristics and t ...... t failure trial (PARADIGM-HF).
@en
type
label
Baseline characteristics and t ...... t failure trial (PARADIGM-HF).
@ast
Baseline characteristics and t ...... t failure trial (PARADIGM-HF).
@en
prefLabel
Baseline characteristics and t ...... t failure trial (PARADIGM-HF).
@ast
Baseline characteristics and t ...... t failure trial (PARADIGM-HF).
@en
P2093
P2860
P356
P1476
Baseline characteristics and t ...... rt failure trial (PARADIGM-HF)
@en
P2093
Adel R Rizkala
Akshay S Desai
Jean L Rouleau
Jianjian Gong
Karl Swedberg
Martin Lefkowitz
Milton Packer
PARADIGM-HF Committees Investigators
Scott D Solomon
Victor C Shi
P2860
P304
P356
10.1002/EJHF.115
P577
2014-06-03T00:00:00Z